Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Nordio

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
European Heart Journal. Acute Cardiovascular Care|July 25, 2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.
Journal of the American Heart Association|July 13, 2016
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
Plos One|September 15, 2018
Outdoor particulate matter (PM10) exposure and lung cancer risk in the EAGLE studyDario Consonni, Michele Carugno, Sara De Matteis, et al.
Journal of Applied Toxicology : JAT|February 12, 2014
Microvesicle-associated microRNA expression is altered upon particulate matter exposure in healthy workers and in A549 cellsValentina Bollati, Laura Angelici, Giovanna Rizzo, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 6, 2019
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialAndré M Nicolau, Ramon Corbalan, Jose C Nicolau, et al.
Journal of the American Heart Association|May 22, 2016
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialEri Toda Kato, Robert P Giugliano, Christian T Ruff, et al.
Lancet (London, England)|March 15, 2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialJessica L Mega, Joseph R Walker, Christian T Ruff, et al.
Journal of the American College of Cardiology|July 13, 2019
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseArman Qamar, Elliott M Antman, Christian T Ruff, et al.
Circulation|November 12, 2019
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER TrialNicholas A Marston, Frederick K Kamanu, Francesco Nordio, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
European Heart Journal. Acute Cardiovascular Care|July 25, 2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.
Journal of the American Heart Association|July 13, 2016
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
Plos One|September 15, 2018
Outdoor particulate matter (PM10) exposure and lung cancer risk in the EAGLE studyDario Consonni, Michele Carugno, Sara De Matteis, et al.
Journal of Applied Toxicology : JAT|February 12, 2014
Microvesicle-associated microRNA expression is altered upon particulate matter exposure in healthy workers and in A549 cellsValentina Bollati, Laura Angelici, Giovanna Rizzo, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 6, 2019
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialAndré M Nicolau, Ramon Corbalan, Jose C Nicolau, et al.
Journal of the American Heart Association|May 22, 2016
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialEri Toda Kato, Robert P Giugliano, Christian T Ruff, et al.
Lancet (London, England)|March 15, 2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialJessica L Mega, Joseph R Walker, Christian T Ruff, et al.
Journal of the American College of Cardiology|July 13, 2019
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseArman Qamar, Elliott M Antman, Christian T Ruff, et al.
Circulation|November 12, 2019
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER TrialNicholas A Marston, Frederick K Kamanu, Francesco Nordio, et al.
Pageof 6